All HHS Contracts — May 20, 2026

Cost-plus-fixed-fee structure reduces profit risk; long performance period through 2032 provides sustained revenue visibility in a high-priority HHS/ASPR/BARDA area.

Full-and-open competition win signals technical merit; $69.7M obligated out of $112.6M max provides near-term revenue visibility for privately held Deloitte.

Small, minority-owned HUBZone firm secures long-term fixed-price contract; $68.4M obligated out of $133.7M max provides multi-year revenue stream for a small business.

With $62.6M obligated and contract expiring May 2025, SELUX faces a potential revenue cliff unless options are exercised or follow-on awards secured.

Two of four contracts ($134.8M total) are from BARDA, creating agency concentration risk for investors tracking HHS exposure.

SOFTRAMS LLC's $68.4M fixed-price delivery order carries medium execution risk; cost overruns could compress margins for this small business.

SELUX Diagnostics contract ends May 2025 with only $23.5M outlayed of $62.6M obligated; remaining $39.1M may be at risk if options are not exercised or budget priorities shift.

Deloitte's NIH NCI BPA nears end in 2026/2027; re-compete could invite protests or competitive displacement, threatening $69.7M revenue stream.

Venatorx Pharmaceuticals' $72.1M BARDA contract with $318.6M ceiling through 2032 offers multi-year revenue growth in AMR biodefense, a bipartisan priority.

SOFTRAMS LLC's $133.7M CMS IT contract through 2029 signals sustained demand for specialized IT services in healthcare administration, benefiting small business IT contractors.

BARDA's dual investment in Venatorx ($72.1M) and SELUX ($62.6M) for medical countermeasures suggests growing biodefense spending, creating opportunities for biotech R&D firms.

Two of four contracts ($134.8M total) are BARDA awards for antimicrobial resistance and medical countermeasures, reflecting sustained government investment in health security.

Two contracts ($138.1M total) from NIH and CMS for IT services, with SOFTRAMS LLC as a HUBZone small business, indicate HHS reliance on small, specialized IT firms for digital transformation.

{"entity"=>"Venatorx Pharmaceuticals", "reason"=>"$72.1M BARDA contract with $318.6M ceiling through 2032; option exercises and clinical milestones are key catalysts.", "trigger"=>"Option exercise announcements; clinical or regulatory milestones for antibiotic candidate; BARDA budget for AMR programs"}

{"entity"=>"SELUX Diagnostics", "reason"=>"$62.6M contract ends May 2025; potential revenue cliff unless options exercised or follow-on awards secured.", "trigger"=>"Contract modifications or extensions beyond May 2025; new BARDA awards; financial disclosures"}

{"entity"=>"Deloitte & Touche", "reason"=>"$69.7M NIH NCI BPA nears end in 2026/2027; re-compete could affect revenue stream.", "trigger"=>"NIH NCI follow-on IT BPA award announcements; protests or competitive dynamics"}

{"entity"=>"SOFTRAMS LLC", "reason"=>"$68.4M CMS fixed-price contract through 2029; execution risk on fixed-price terms.", "trigger"=>"Obligated vs. outlayed gap monitoring; CMS budget for IT services; re-compete announcements"}